{{Chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 406013101
| ImageFile = Epalrestat.svg
| ImageSize = 222
| IUPACName = 2-[(5''Z'')-5-[(''E'')-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
| OtherNames =

|Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 424DV0807X
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 82159-09-9
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01688
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 31539
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 56337
| PubChem = 1549120
| SMILES = O=C(O)CN1C(=O)C(\SC1=S)=C/C(=C/c2ccccc2)C
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 1266086
|  InChI = 1/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
|  InChIKey = CHNUOJQWGUIOLD-NFZZJPOKBR
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = CHNUOJQWGUIOLD-NFZZJPOKSA-N

 }}

|Section2 = {{Chembox Properties
| Formula = C<sub>15</sub>H<sub>13</sub>NO<sub>3</sub>S<sub>2</sub>
| MolarMass = 319.401 g/mol
| Appearance =
| Density = 1.43 g/cm<sup>3</sup>
| MeltingPtC = 210
| BoilingPtC = 516.8
| Solubility = 
 }}

|Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
 }}
}}

'''Epalrestat''' is a carboxylic acid derivative<ref>{{cite journal|last1=Terashima|first1=H|last2=Hama|first2=K|title=Effects of a new aldose reductase inhibitor on various tissue in vitro|journal=J Pharamacol Exp Ther|date=1984|volume=229|pages=226–230}}</ref> and a noncompetitive and reversible [[aldose reductase inhibitor]] used for the treatment of [[diabetic neuropathy]], which is one of the most common long-term complications in patients with [[diabetes mellitus]]. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy <ref>{{cite journal|last1=Ramirez|first1=Mary Ann|last2=Borja|first2=Nancy L|title=Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy|journal=Pharmacotherapy|date=May 2008|volume=28|issue=5|pages=646–655|doi=10.1592/phco.28.5.646}}</ref><ref>{{cite journal|last1=Steele|first1=John W.|last2=Faulds|first2=Diana|last3=Goa|first3=Karen L.|title=Epalrestat|journal=Drugs & Aging|date=1993|volume=3|issue=6|pages=532–555|doi=10.2165/00002512-199303060-00007}}</ref> It is well tolerated, with the most commonly reported adverse effects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes.<ref>{{cite journal|last1=Ramirez|first1=Mary Ann|last2=Borja|first2=Nancy L|title=Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy|journal=Pharmacotherapy|date=May 2008|volume=28|issue=5|pages=646–655|doi=10.1592/phco.28.5.646}}</ref>
Chemically, epalrestat is unusual in that it is a drug that contains a [[rhodanine]] group.
Aldose reductase is the key enzyme in the polyol pathway whose enhanced activity is the basis of diabetic neuropathy. Aldose reductase inhibitors (ARI) target this enzyme. Out of the many ARIs developed, ranirestat and fidarestat are in the trial stage. Others have been discarded due to unacceptable adverse effects or weak efficacy. Epalrestat is the only ARI commercially available.<ref>{{cite journal|last1=Hotta|first1=N|last2=Akanuma|first2=Y|last3=Kawamori|first3=R|last4=Matsuoka|first4=K|last5=Oka|first5=Y|last6=Shichiri|first6=M|title=Long-Term Clinical Effects of Epalrestat, an|journal=Diabetes Care|date=July 2006|volume=29|issue=7|pages=1538–44|doi=10.2337/dc05-2370|pmid=16801576|url=http://care.diabetesjournals.org/content/29/7/1538.long|accessdate=16 July 2016}}</ref> It is easily absorbed into the neural tissue<ref>{{cite journal|last1=Terashima|first1=H|last2=Hama|first2=K|last3=Yamamoto|first3=R|last4=Tsuboshima|first4=M|last5=Kikkawa|first5=R|last6=Hatanaka|first6=I|title=Effects of a new aldose reductase inhibitor on various tissues in vitro.|journal=J Pharmacol Exp Ther|date=1984|volume=229|pages=226–30}}</ref> and inhibits the enzyme with minimum side effects.<ref>{{cite journal|last1=Hotta|first1=N|last2=Sakamoto|first2=N|last3=Shigeta|first3=Y|last4=Kikkawa|first4=G|last5=Goto|first5=Y|last6=Diabetic Neuropathy Study|title=Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study.|journal=J Diabetes Complications|date=1996|volume=10|pages=168–72|doi=10.1016/1056-8727(96)00113-4}}</ref>

== Evidence ==
It has been proven in animal experiments that there is an improvement in sorbitol levels and Na+/K+ ATPase activity leading to improved nerve conduction velocity. Diabetic rats treated with epalrestat showed improvement in morphological abnormalities of nerves.<ref>{{cite book|last1=Hotta|first1=N|last2=Sugimura|first2=K|last3=Kakuta|first3=H|last4=Fukasawa|first4=H|last5=Kimura|first5=M|last6=Koh|first6=N|title=Effects of a fructose rich diet and an aldose reductase inhibitor on the development of diabetic neuropathy in streptozotocin-treated rats.|date=1988|publisher=Elsevier Science Publishers BV|location=Amsterdam|page=511|accessdate=6 July 2016}}</ref> 
In a placebo controlled double blind trial of 196 patients, it was proved that Epalrestat in a dose of 150&nbsp;mg/day improved the effects of diabetic neuropathy like upper limb spontaneous pain, motor nerve conduction velocity, thresholds of vibratory sensation and autonomic nerve function as compared to a placebo. These effects were significantly better in those with poorer control of diabetes.<ref>{{cite journal|last1=Goto|first1=Y|last2=Hotta|first2=N|last3=Shigeta|first3=Y|last4=Sakamoto|first4=N|last5=Kikkawa|first5=R|title=Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.|journal=Biomed Pharmacother|date=1995|volume=49|issue=6|pages=269–77|doi=10.1016/0753-3322(96)82642-4|pmid=7579007}}</ref>
A systematic review and metaanalysis showed that based on the results of 10 articles, it can be concluded that Epalrestat has some benefit in the control of diabetic cardiovascular autonomic neuropathy but only in the early or mild cases. It also doesn't influence glycaemic control.<ref>{{cite journal|last1=Xin|first1=Hu|last2=Li|first2=Shengbing|last3=Yang|first3=Gangyi|last4=Liu|first4=Hua|last5=Boden|first5=Guenther|last6=Li|first6=Ling|title=Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis|journal=PLOS ONE|date=2014|volume=9|issue=2|page=e87096.|doi=10.1371/journal.pone.0087096|pmc=3922720|pmid=24533052}}</ref>

== Brand names ==
* '''Aldonil''' (Zydus Medica), India
* '''Aldorin''', Bangladesh
* '''Alrista''' (marketed and not manufactured by Macleods), India
* '''Epalrica-M''' (Ordain Global), India
* '''Eparel 50''' (Microlabs Ltd), India
* '''Epimeth''' (Zaiva Lifesciences), India
* '''Eplistat 150 SR''' (Schem), India
* '''Letostat-SR''' (Amor Pharmaceuticals), India
* '''Listap-50''' (Vivid Biotek), India
* '''Tanglin''' (Yangtze River Pharmaceutical Group), China

==References==
{{reflist}}

==External links==
* [http://www.chemblink.com/products/82159-09-9.htm Epalrestat at chemblink.com]

{{oral hypoglycemics}}

[[Category:Aldose reductase inhibitors]]
[[Category:Alkene derivatives]]
[[Category:Thiazolidines]]


{{gastrointestinal-drug-stub}}